ArticleThe Journal of general virology2026
Evaluation of the contribution of the minor envelope complex glycoprotein 3 ectodomain to the porcine reproductive and respiratory syndrome virus 1 neutralizing antibody response.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome viruses (PRRSVs) cause significant economic losses to the global swine industry. Current live attenuated vaccines are unable to effectively control PRRSV infection, and strain variability, driven by rapid mutation, complicates the development of improved vaccines. Identification of the targets of broadly neutralizing antibodies is crucial for guiding next-generation vaccine design, yet PRRSV glycoproteins bearing conserved neutralizing epitopes remain poorly defined. To address this, recombinant soluble forms of PRRSV-1 envelope glycoproteins, GP2, GP3 and GP4, were produced using mammalian cells. The screening of serum from hyperimmune pigs demonstrated GP3 as the most highly recognized of the three glycoproteins. Fluorescently tagged GP3-tetramers were utilized to isolate single B cells from a hyperimmune pig via flow cytometry. Immunoglobulin VH and VL regions were amplified by RT-PCR and sequenced. Fifteen unique heavy and light chain pairs were cloned and expressed as recombinant monoclonal antibodies (mAbs). mAbs were evaluated for specificity, cross-reactivity and neutralizing capacity. Antigenic sites targeted by GP3-specific mAbs were mapped to several conserved linear sequences, but mAbs did not exhibit virus neutralizing activity
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.